@TitanCompanyLtd
Jewellery saw sharp uptick in Q2fy21 ,98% precovid levels
Added 14 Tanishq stores,8 in Q2
Watches / eyewear recovery sluggish 55/61 % precovid
Mkt share gains for organized players,strong balance sheet,franchisee model,digital spending,ecommerce driving sales
Rise in gold prices led to robust gold jewellery & coin sales
Smaller towns driving demand
Recovery 77% in Jun to 98% in Sep quarter
50% Tanishq stores concentrated in rural areas
Wedding season ,diwali to further boost jewellery demand
#titan #Nifty #sensex #StockMarket
Reopening of stores, malls, vaccine may increase footfalls in Q3,Q4
Launched 'Gift a Titan' & new jewellery division ' Rooted from Zoya'
Launched its 1st smartwatch 'Titan connected X'
Taneira launched 1st Chennai store ,total 13 stores functional
Net sales down 2.6% ,PAT down 37% ,Ebidta margin down 480bps ,jewellery sales up 8.8% to 38.4bn on 38% higher gold prices
Watches sales down 44.3%
Expects to add 34 stores in Fy21,14 added so far
@TitanCompanyLtd #market #dalalstreet

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with TheMarket🐝

TheMarket🐝 Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @BullsforBears

31 Dec 20
#glandpharma
Injectable focused B2B company
Mkt includes US,Europe,India,Australia
Niche area - sterile injectables,Oncology,Opthalmic solns
Focus -complex injectables,first to file,NCE-1, 505(b)(2) filings
Chinese promoter Shanghai Fosun Pharma is a global pharma major
#pharma
Fosun acquired controlling stake in gland 74% in 2017 for $1.09 bn
Gland has 267 ANDA filings in the US Mkt, 215 approved
267 filings - 191 sterile injectables, 50 oncology ,26 ophthalmic
Out of 267,101 ANDA are owned by Gland of which 71 approved
Good regulatory compliance
No #USFDA warning letter till date
7 mftng facilities - 4 finished Formulations, 3 API
API facilities 100% captive consumption
63% of Fy20 revenue of 2633 cr were from US mkt
Focus on injs with high entry barrier, limited competition, strict regulatory reqs

#API #cdmo
Read 12 tweets
25 Dec 20
@IndianEnergyXch
Transformation drivers
1) Decarbonization - use of solar & wind ,RE (renewable energy)
2) Decentralisation - RE a threat to centralized energy productn
3) Digitization
4) Democratization- peer 2 peer energy trading
Changing energy mix
2020/ 2022 /2030 % of contribution
Thermal 62 /53 /35
Wind 10 /12 /17
Solar 9 / 20/ 36
Hydro 12 / 10 /8

Electricity value chain 4 parts
Generation - Transmission - Distribution - Consumption

Power sector construct
Long term 90%
Short term 10%
Power markets in developed countries are in range 30 - 80% of total power demand ,India 5%

Share of exchange in total generation
2016 - 2.9 %
2021 - 5.2%
Share of ST market in total generation
2016 - 9.9%
2021 - 10.3%
Exchange mkt & ST MKT as % of total gen
2016 29.9
2021 50.2
Read 12 tweets
24 Dec 20
#Dixon key beneficiary of GOI PLI scheme
Through its subsidiary Padget electronics, Dixon made 2 applications for phones costing < 15000 ,70% India mobile mkt share
Incentive of 4 to 6% under PLI subject to a cap
Total investment 200crs ,50 cr/yr till 2025
#dixontechnologies
Post expansion revenue share of mobiles to jump to 44 from 12% currently
Ramp up capacity from 3 mn today to 15-16 mn over next few yrs ,aim for revenue 28-30000 crs over next 5 yrs
In talks 3 large players

Set top boxes, delivered 5.2 lakh to jio,dish,Citi
Order book 0.3mn/mon
Dixon is both OEM Player & ODM ( original design manufacturer)
Expanding capacities in Android & Linux TV ,semi automatic and top load washing machines
Current capacity 4 mn TV sets ,30%LED Mkt,acquired new customers Samsung,Nokia,Ramos capacity to 5.5 mn
#Nifty #stocks
Read 6 tweets
23 Dec 20
@JubilantLifeSci
Q2fy21 Revenue up 4.8% yoy to 2347.9 crs led by traction in CMO/Generics in Pharma & Life sciences in LSI segment
- Radiopharma business impacted by Covid & launch of macroaggregated Albumin (MAA) by competitor Curium(jubilant was sole player)
#pharma #Nifty
MAA business witnessed price & mkt share erosion
-DTPA business impacted by decrease in ventilation scan due to covid
-Generic business growth led by traction existing products,launch of Remdesivir
-JLS to launch Remdesivir in 70 countries, exported API to US & injs in India
Radiopharma 90% & allergy business 100% precovid levels
-Partnership with SOFIE Biosciences in molecular theranostics
- JLS to double DDDS capacity by Fy22
- LSI business speciality declined 2% & nutritional grew 11% led by VIT D exports to EU while ethyl acetate muted growth
Read 4 tweets
22 Dec 20
@GranulesIndia
Q2fy21
Revenue up 22.7% to 858 crs
Formulations up 22.4% yoy 430 crs
API up 17% to 255
PFI up 32.6% to 173 crs
Vizag unit V commissioned for API ,oncology segment,
Company plans gradual shift from commoditized API to more complex drugs/ Formulations
#stocks
Company expects to commission MUPS block by Q3fy22
- Revenue contribution of core mols dropped to 70 from 80-85% end of Fy20
- #granules has 32 ANDA approved ,expect to launch 6 of these in Fy21
- Revised PAT guidance to 30% post Fy21 from 25% earlier
#StockMarket #Nifty
Company plans 7-9 product filings/year, atleast 5 for the US market
- Top 5 mols contributed 70%
- Capex guidance of 3.5 to 4 bn for fy21 & 3bn for Fy22
- Relaunch Metformin 750 mg in US over next year
- EU sales 23 % expected to reach 28% by Fy23, US sales to decline to 43%
Read 7 tweets
12 Dec 20
#amberenterprises Q2fy21 concall transcript

Q2 went well for Room AC industry,uptick retail demand, pent up demand
Overall electronic & consumer durables witnessed a good quarter
Inventory levels back to normal
Anticipate better H2fy21
#stock #StocksToWatch #Nifty #sensex
GOI banned import of refrigerant fill ACs, approx 30% of fully built RACs were imported mkt size 4000 crs , atmanirbhar bharat initiative,oppurtunity for domestic RAC players
Not easy for OEMs to import non-refrigerant fill ACs,unpack,gas fill test,negates cost advantage
#amberenterprises completed QIP 400 cr in Q2fy21, money used for debt repayment,capex,WC ,acquire additional 20% stake in Sidwal,company ready to grab mkt share in RAC
China plus 1 unfolding,global MNC enquiring about RAC & components
Amber started export of components to US
Read 16 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!